Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals...


Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals (AMLN) after reciving tenders for 85.55% of the latter's shares. Under the deal, AztraZenica (AZN) will now pay $3.4B to Bristol-Myers as part of a collaboration agreement for the development and commercialization of Amylin's products. (PR)

From other sites
Comments (1)
  • Occamsrazor
    , contributor
    Comments (887) | Send Message
     
    I like low P/E drug stocks with good dividends.
    8 Aug 2012, 06:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs